Summary: Centessa Pharmaceuticals has made progress in its orexin receptor 2 agonist program, focusing on the development of treatments for sleep-wake disorders such as narcolepsy and idiopathic hypersomnia. The company has initiated a phase 1 clinical trial for ORX750, with … [Read more...]